Detail akcie Labcorp Hldgs online

Business Summary: Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Labcorp Holdings Inc revenues increased 6% to $3.54B. Net income increased 31% to $277.8M. Revenues reflect DX segment increase of 5% to $2.76B, BLS segment increase of 8% to $780.6M. Net income benefited from DX segment income increase of 7% to $458.7M, BLS segment income increase of 13% to $120.7M, General corporate segment loss decrease of 5% to $198.6M. Dividend per share remained flat at $0.72.